Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alzheimer's Tau Platform: Regimen A - AADvac1
Sponsor: Paul S. Aisen
Summary
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Official title: Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
450
Start Date
2026-11-03
Completion Date
2028-08-31
Last Updated
2026-09-08
Healthy Volunteers
No
Interventions
AADvac1
Subcutaneous injection of AADvac1
Donanemab
Active comparator: intravenous infusion of donanemab
Locations (3)
University of California, San Francisco (UCSF), Memory and Aging Center
San Francisco, California, United States
Butler Hospital Memory and Aging Program
Providence, Rhode Island, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States